Compare AUR & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AUR | MDGL |
|---|---|---|
| Founded | 2017 | 2011 |
| Country | United States | United States |
| Employees | 1900 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.2B | 11.5B |
| IPO Year | N/A | 2005 |
| Metric | AUR | MDGL |
|---|---|---|
| Price | $7.08 | $516.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | $9.43 | ★ $674.45 |
| AVG Volume (30 Days) | ★ 29.5M | 264.2K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 41.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $180,133,000.00 |
| Revenue This Year | $407.30 | $58.39 |
| Revenue Next Year | $1,134.58 | $48.55 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.60 | $265.00 |
| 52 Week High | $8.57 | $615.00 |
| Indicator | AUR | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 57.84 | 51.29 |
| Support Level | $5.17 | $498.34 |
| Resistance Level | $8.57 | $554.40 |
| Average True Range (ATR) | 0.55 | 23.54 |
| MACD | -0.09 | -1.47 |
| Stochastic Oscillator | 30.00 | 41.89 |
Aurora Innovation Inc delivers self-driving technology safely, quickly, and broadly. The Aurora Driver is a self-driving system designed to operate multiple vehicle types, from freight-hauling trucks to ride-hailing passenger vehicles. It underpins Aurora Horizon and Aurora Connect, its driver-as-a-service products for trucking and ride-hailing. The Company is developing the Aurora Driver, a scalable suite of self-driving hardware, software, and data services designed as a platform to adapt and interoperate among vehicle types and applications.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.